Health-Related Quality of Life up to Six Years After 125I Brachytherapy for Early-Stage Prostate Cancer

This is the first study presenting prospective HRQOL data up to 6 years after 125I prostate brachytherapy. HRQOL scores returned to approximately baseline values at 1 year and remained stable up to 6 years after treatment. 125I prostate brachytherapy did not adversely affect patients' long-term HRQOL.